U.S. Markets close in 6 hrs 23 mins

Moleculin (MBRX) Looks Good: Stock Adds 5.3% in Session

Zacks Equity Research

Moleculin Biotech, Inc. MBRX was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of 40 cents–$1.27 in the past one-month time frame, witnessed a sharp increase yesterday.

The company has seen two positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the same time frame, suggesting that more solid trading could be ahead for Moleculin. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.

Moleculin currently has a Zacks Rank #1 (Strong Buy) while its Earnings ESP is 0.00%.

Moleculin Biotech, Inc. Price

Moleculin Biotech, Inc. Price

Moleculin Biotech, Inc. price | Moleculin Biotech, Inc. Quote

Another stock worth considering in the Medical sector is Celldex Therapeutics, Inc. CLDX, which currently carries a Zacks Rank #1. You can see the complete list of today’s Zacks #1 Rank stocks here.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics, Inc. (CLDX) : Free Stock Analysis Report
Moleculin Biotech, Inc. (MBRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.